Praxis Precision Medicines (PRAX) EBITDA (2019 - 2026)

Praxis Precision Medicines' EBITDA history runs 8 years deep, the most recent figure standing at -$94.7 million for Q1 2026.

• In Q1 2026, EBITDA fell 36.7% year-over-year to -$94.7 million; the TTM figure through Mar 2026 stood at -$346.2 million (down 52.12% YoY), while the FY2025 annual figure was -$326.2 million, down 62.96% from the prior year.
• EBITDA was -$94.7 million for Q1 2026 at Praxis Precision Medicines, up from -$97.0 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$25.5 million in Q3 2023 to a low of -$97.0 million in Q4 2025.
• Historically, EBITDA has averaged -$56.3 million across 5 years, with a median of -$56.8 million in 2024.
• The sharpest annual moves came in 2022 and 2023: EBITDA tumbled 151.82% in 2022, then jumped 44.91% in 2023.
• A 5-year view of EBITDA shows it stood at -$41.5 million in 2022, then soared by 32.92% to -$27.8 million in 2023, then tumbled by 130.01% to -$64.0 million in 2024, then plunged by 51.74% to -$97.0 million in 2025, then gained by 2.4% to -$94.7 million in 2026.
• The last three EBITDA figures came in at -$94.7 million (Q1 2026), -$97.0 million (Q4 2025), and -$78.4 million (Q3 2025), per Business Quant data.